(Q37060317)

English

Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature

scientific article published on 19 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

1 reference

Europe PubMed Central

Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

systematic review

1 reference

based on heuristic

inferred from title

author name string

J Kay Noel

1

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Sheila Crean

2

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Janet E Claflin

3

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Gayatri Ranganathan

4

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Heather Linz

5

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Michael Lahn

6

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

publication date

19 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

323-330

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Systematic reviews: synthesis of best evidence for clinical decisions

1 reference

https://api.crossref.org/works/10.1007%2FS12032-008-9039-1

21 January 2018

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p38 MAP kinase: a convergence point in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p38 MAP kinase inhibitors: many are made, but few are chosen.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide and Its Derivatives: New Promise for Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thromboembolism in patients on thalidomide for myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide as a novel therapeutic agent: new uses for an old product

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide is an inhibitor of angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of the effectiveness of animal developmental toxicity testing for human safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide therapy and polyneuropathy in myeloma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential of p38 MAP kinase inhibitors in the treatment of cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide: present and future in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of thalidomide toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dermatologic side effects of thalidomide in patients with multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial design in cancer drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p38 MAP kinase's emerging role as a tumor suppressor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide-induced severe neutropenia during treatment of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Map kinase signaling pathways and hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide and its derivatives: emerging from the wilderness

1 reference

https://pubmed.ncbi.nlm.nih.gov/18204822

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-008-9039-1

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37060317&oldid=2199815509"